[{"id":"264b6c87-54a5-4e3b-9928-8b444e1c65f6","acronym":"ROYAL","url":"https://clinicaltrials.gov/study/NCT07151911","created_at":"2025-09-06T13:40:25.560Z","updated_at":"2025-09-06T13:40:25.560Z","phase":"","brief_title":"Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients","source_id_and_acronym":"NCT07151911 - ROYAL","lead_sponsor":"Azienda Ospedaliero-Universitaria di Modena","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/26/2024","start_date":" 08/26/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2031","study_completion_date":" 09/01/2031","last_update_posted":"2025-09-03"},{"id":"306f2837-4ae2-43cc-8471-5706f09281e5","acronym":"ELAINE 3","url":"https://clinicaltrials.gov/study/NCT05696626","created_at":"2023-01-25T16:59:42.976Z","updated_at":"2025-02-25T12:38:31.246Z","phase":"Phase 3","brief_title":"Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation","source_id_and_acronym":"NCT05696626 - ELAINE 3","lead_sponsor":"Sermonix Pharmaceuticals Inc.","biomarkers":" ER","pipe":" | ","alterations":" ESR1 mutation","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • Fablyn (lasofoxifene)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-24"},{"id":"7a55dd21-17fa-4758-9f8c-76ac780a7858","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750928","created_at":"2021-02-11T12:52:56.866Z","updated_at":"2025-02-25T12:27:56.800Z","phase":"Phase 1/2","brief_title":"Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas","source_id_and_acronym":"NCT04750928","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-24"},{"id":"7e70ebdc-cdaa-4580-9eb1-432961d43354","acronym":"CAMBRIA-2","url":"https://clinicaltrials.gov/study/NCT05952557","created_at":"2023-07-20T14:08:53.643Z","updated_at":"2025-02-25T14:18:07.526Z","phase":"Phase 3","brief_title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","source_id_and_acronym":"NCT05952557 - CAMBRIA-2","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 5500","initiation":"Initiation: 10/05/2023","start_date":" 10/05/2023","primary_txt":" Primary completion: 03/04/2030","primary_completion_date":" 03/04/2030","study_txt":" Completion: 05/06/2037","study_completion_date":" 05/06/2037","last_update_posted":"2025-02-18"},{"id":"accc8beb-5a40-4334-a4ae-f00e0d7cc772","acronym":"ELEVATE","url":"https://clinicaltrials.gov/study/NCT05563220","created_at":"2022-10-03T15:56:32.608Z","updated_at":"2025-02-25T14:17:18.649Z","phase":"Phase 1/2","brief_title":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT05563220 - ELEVATE","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER • PIK3CA • CDK4","pipe":" | ","alterations":" PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • Truqap (capivasertib) • Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 01/24/2023","start_date":" 01/24/2023","primary_txt":" Primary completion: 12/27/2026","primary_completion_date":" 12/27/2026","study_txt":" Completion: 12/28/2028","study_completion_date":" 12/28/2028","last_update_posted":"2025-02-18"},{"id":"80ed7c63-7fb5-4c5d-85cd-7d59cce7c2c5","acronym":"CAROLEEN","url":"https://clinicaltrials.gov/study/NCT06830720","created_at":"2025-02-25T14:20:53.607Z","updated_at":"2025-02-25T14:20:53.607Z","phase":"","brief_title":"A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence","source_id_and_acronym":"NCT06830720 - CAROLEEN","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Kisqali (ribociclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 3250","initiation":"Initiation: 02/09/2025","start_date":" 02/09/2025","primary_txt":" Primary completion: 05/31/2030","primary_completion_date":" 05/31/2030","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-02-17"},{"id":"d5e3296e-7887-47f7-a8e8-e85cdb5b5e2b","acronym":"MORPHEUS BC","url":"https://clinicaltrials.gov/study/NCT04802759","created_at":"2021-03-17T15:57:40.908Z","updated_at":"2025-02-25T12:28:00.493Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","source_id_and_acronym":"NCT04802759 - MORPHEUS BC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ER • CDK4","pipe":" | ","alterations":" HER-2 positive • ER positive","tags":["ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (RG6171) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-17"},{"id":"a9a958a0-54fc-401f-80e7-fc0331ae93eb","acronym":"MyDRUG","url":"https://clinicaltrials.gov/study/NCT03732703","created_at":"2021-01-18T18:17:27.493Z","updated_at":"2025-02-25T13:18:42.828Z","phase":"Phase 1/2","brief_title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","source_id_and_acronym":"NCT03732703 - MyDRUG","lead_sponsor":"Multiple Myeloma Research Consortium","biomarkers":" BRAF • SLC1A5","pipe":"","alterations":" ","tags":["BRAF • SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-14"},{"id":"e2cd3260-cd72-4639-a5ac-6d252bb0c83c","acronym":"ELAINEII","url":"https://clinicaltrials.gov/study/NCT04432454","created_at":"2021-01-18T21:20:42.852Z","updated_at":"2025-02-25T14:51:49.300Z","phase":"Phase 2","brief_title":"Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","source_id_and_acronym":"NCT04432454 - ELAINEII","lead_sponsor":"Sermonix Pharmaceuticals Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Fablyn (lasofoxifene)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 09/29/2020","start_date":" 09/29/2020","primary_txt":" Primary completion: 01/28/2025","primary_completion_date":" 01/28/2025","study_txt":" Completion: 01/28/2025","study_completion_date":" 01/28/2025","last_update_posted":"2025-02-13"},{"id":"a22b0db3-f6b3-489e-b362-7e9a7131a6f7","acronym":"ELECTRA","url":"https://clinicaltrials.gov/study/NCT05386108","created_at":"2022-05-23T15:53:51.405Z","updated_at":"2025-02-25T15:27:22.960Z","phase":"Phase 1/2","brief_title":"Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer","source_id_and_acronym":"NCT05386108 - ELECTRA","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-11"},{"id":"996991a4-16ed-4414-90f1-2f630a1b4a1d","acronym":"lidERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04961996","created_at":"2021-07-14T14:53:31.141Z","updated_at":"2025-02-25T15:35:10.567Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","source_id_and_acronym":"NCT04961996 - lidERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 4200","initiation":"Initiation: 08/27/2021","start_date":" 08/27/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 11/21/2033","study_completion_date":" 11/21/2033","last_update_posted":"2025-02-10"},{"id":"f6a27acf-7978-4c4b-a907-56c547d54b2a","acronym":"Morpheus-TNBC","url":"https://clinicaltrials.gov/study/NCT03424005","created_at":"2021-01-18T16:53:25.262Z","updated_at":"2025-02-25T15:17:38.740Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT03424005 - Morpheus-TNBC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • PIK3CA","pipe":" | ","alterations":" PD-L1 expression • PIK3CA mutation","tags":["HER-2 • PD-L1 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)"],"overall_status":"Recruiting","enrollment":" Enrollment 580","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 05/03/2028","primary_completion_date":" 05/03/2028","study_txt":" Completion: 05/03/2028","study_completion_date":" 05/03/2028","last_update_posted":"2025-02-10"},{"id":"08f4f7cb-1de9-4017-ba99-77f7d20628d0","acronym":"ARTS-021-1001","url":"https://clinicaltrials.gov/study/NCT05867251","created_at":"2023-05-19T13:05:01.323Z","updated_at":"2025-02-25T16:46:48.865Z","phase":"Phase 1/2","brief_title":"Study of AVZO-021 in Patients with Advanced Solid Tumors","source_id_and_acronym":"NCT05867251 - ARTS-021-1001","lead_sponsor":"Avenzo Therapeutics, Inc.","biomarkers":" HER-2 • CCNE1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • carboplatin • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • Trodelvy (sacituzumab govitecan-hziy) • AVZO-021"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 08/30/2023","start_date":" 08/30/2023","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2025-02-05"},{"id":"0d7fca80-0420-4ead-a6c7-20e34e32d1a2","acronym":"pionERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06065748","created_at":"2023-10-04T16:11:25.824Z","updated_at":"2025-02-25T16:47:04.424Z","phase":"Phase 3","brief_title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","source_id_and_acronym":"NCT06065748 - pionERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 1050","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-05"},{"id":"4f30abc8-8e7a-46eb-9dd2-cdd5a80eaef4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06810544","created_at":"2025-02-25T16:50:18.957Z","updated_at":"2025-02-25T16:50:18.957Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","source_id_and_acronym":"NCT06810544","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" MTAP","pipe":"","alterations":" ","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 191","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-05"},{"id":"5b3bbfcb-81b9-4094-b5ab-f48bff41c08a","acronym":"NCI-2022-04099","url":"https://clinicaltrials.gov/study/NCT05372640","created_at":"2022-05-13T12:54:24.439Z","updated_at":"2025-02-25T16:46:03.280Z","phase":"Phase 1","brief_title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","source_id_and_acronym":"NCT05372640 - NCI-2022-04099","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NUTM1","pipe":"","alterations":" ","tags":["NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-05"},{"id":"4b0f1350-ce19-4057-8fd9-f2b662d41e4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06025747","created_at":"2023-09-06T14:09:40.441Z","updated_at":"2025-02-25T16:55:17.296Z","phase":"Phase 1","brief_title":"Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma","source_id_and_acronym":"NCT06025747","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" MDM2 • CDK4","pipe":" | ","alterations":" CDK4 amplification","tags":["MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/09/2025","start_date":" 02/09/2025","primary_txt":" Primary completion: 03/03/2025","primary_completion_date":" 03/03/2025","study_txt":" Completion: 03/03/2026","study_completion_date":" 03/03/2026","last_update_posted":"2025-02-04"},{"id":"c392c236-bf01-4f33-b758-84c02e4596c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03939897","created_at":"2021-01-18T19:24:01.905Z","updated_at":"2025-02-25T16:52:29.645Z","phase":"Phase 1","brief_title":"Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer","source_id_and_acronym":"NCT03939897","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PIK3CA • PGR • PTEN","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PGR positive","tags":["HER-2 • ER • PIK3CA • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/17/2020","start_date":" 06/17/2020","primary_txt":" Primary completion: 06/22/2023","primary_completion_date":" 06/22/2023","study_txt":" Completion: 07/16/2025","study_completion_date":" 07/16/2025","last_update_posted":"2025-02-04"},{"id":"7d906406-3512-4d2f-bf49-f76062d2546f","acronym":"MCC-20899","url":"https://clinicaltrials.gov/study/NCT04923542","created_at":"2021-06-11T18:56:15.461Z","updated_at":"2025-02-25T17:37:10.115Z","phase":"Phase 1/2","brief_title":"Stereotactic Radiation \u0026 Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases","source_id_and_acronym":"NCT04923542 - MCC-20899","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-01-29"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"45b9e4e8-9732-4ed9-b569-eae18917beb8","acronym":"KEYNOTE E27","url":"https://clinicaltrials.gov/study/NCT04956640","created_at":"2021-07-09T12:57:24.328Z","updated_at":"2025-02-25T16:16:26.190Z","phase":"Phase 1/2","brief_title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","source_id_and_acronym":"NCT04956640 - KEYNOTE E27","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 550","initiation":"Initiation: 07/19/2021","start_date":" 07/19/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-28"},{"id":"298b3e73-8efc-4e73-b46a-0f8a07bcd548","acronym":"EMBER-3","url":"https://clinicaltrials.gov/study/NCT04975308","created_at":"2021-07-23T13:52:36.804Z","updated_at":"2025-02-25T16:16:28.798Z","phase":"Phase 3","brief_title":"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT04975308 - EMBER-3","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • exemestane • Inluriyo (imlunestrant)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 866","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 06/24/2024","primary_completion_date":" 06/24/2024","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-01-24"},{"id":"8a9f44be-fc46-4b3c-891d-8961656bffed","acronym":"KEYNOTE 287","url":"https://clinicaltrials.gov/study/NCT02779751","created_at":"2021-01-17T18:04:05.704Z","updated_at":"2025-02-25T16:04:45.290Z","phase":"Phase 1","brief_title":"A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer","source_id_and_acronym":"NCT02779751 - KEYNOTE 287","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • PD-L1 • KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["HER-2 • PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Verzenio (abemaciclib) • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 02/03/2020","primary_completion_date":" 02/03/2020","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-01-24"},{"id":"c86caf36-50f7-4e83-bb56-4d558b8c9be3","acronym":"EMBER","url":"https://clinicaltrials.gov/study/NCT04188548","created_at":"2021-01-18T20:25:02.359Z","updated_at":"2025-02-25T13:53:03.697Z","phase":"Phase 1","brief_title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","source_id_and_acronym":"NCT04188548 - EMBER","lead_sponsor":"Eli Lilly and Company","biomarkers":" ER","pipe":" | ","alterations":" HER-2 negative • EGFR positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • everolimus • Perjeta (pertuzumab) • Piqray (alpelisib) • Verzenio (abemaciclib) • exemestane • Inluriyo (imlunestrant)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 12/10/2019","start_date":" 12/10/2019","primary_txt":" Primary completion: 06/29/2020","primary_completion_date":" 06/29/2020","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-01-22"}]